Cover Image
市場調查報告書

全球小鼠模型市場 : 各類型(近交類、基因剔除、混合)、各技術(顯微注射、ES細胞)、各疾病(腫瘤學、糖尿病)、各服務類別(繁殖、冷凍保存、遺傳基因檢驗)、各照顧產品(床、飼料)分析及預測

Mice Model Market by Type (Inbred, Knockout, Hybrid), Technology (Microinjection, Embryonic stem Cell), Disease (Oncology, Diabetes), Service (Breeding, Quarantine, Genetic testing) & Care Products (Bedding, Feed) - Analysis & Global Forecast to 2020

出版商 MarketsandMarkets 商品編碼 293088
出版日期 內容資訊 英文 249 Pages
訂單完成後即時交付
價格
Back to Top
全球小鼠模型市場 : 各類型(近交類、基因剔除、混合)、各技術(顯微注射、ES細胞)、各疾病(腫瘤學、糖尿病)、各服務類別(繁殖、冷凍保存、遺傳基因檢驗)、各照顧產品(床、飼料)分析及預測 Mice Model Market by Type (Inbred, Knockout, Hybrid), Technology (Microinjection, Embryonic stem Cell), Disease (Oncology, Diabetes), Service (Breeding, Quarantine, Genetic testing) & Care Products (Bedding, Feed) - Analysis & Global Forecast to 2020
出版日期: 2016年01月22日 內容資訊: 英文 249 Pages
簡介

人類和老鼠的生物結構,在生理學及遺傳的特徵中有顯著類似之點,為了能解明人的疾病流程,小鼠模型成為在研究活動中的必須工具。活用這樣的優點,可加深科學發現各個的遺傳基因的作用,各種疾病的機制,理解各種藥物分子的效果與毒性等。小鼠模型具有小、短世代時間、加速的壽命、低成本、省空間等優點而最常使用,成為促進藥物療法研究開發的要素。小鼠模型的全球市場,2015年達到10億5,000萬美元的規模,此後預計以年複合成長率7.1%成長,2020年達到14億9,000萬美元。

本報告以全球小鼠模型市場為主題,提供市場龐大的小鼠模市場與服務的市場兩者,在各類型、各技術、各疾病、各服務類別、各地區中的市場現況與展望相關調查分析,競爭環境,主要企業簡介等彙整結果,為您概述為以下內容。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 高級見解

  • 全球小鼠模型市場
  • 地區分析:口腔保健產品市場(各類型)
  • 小鼠模型市場:各技術(實際成果及預測)

第5章 市場概要

  • 簡介
  • 市場區隔
  • 市場動態
    • 市場發展推動因素
      • 小鼠模型的持續中創新
      • 根據個體化醫療定做的人體化小鼠模型需求促進
      • 輔助金及投資形式的持續支援
      • 製藥公司的活躍研究開發活動
      • 不僅是ES細胞,基因剔除/突變老鼠的開發相關學會的重要性高漲
    • 市場發展阻礙因素
      • 老鼠模型利用的增加
      • 斑馬菲什模式開發的進步
      • 冷凍保存的恩惠增加
      • 調查中動物的倫理使用相關法規
      • 動物實驗的替代法
    • 市場機會
      • 人體化小鼠模型的需求增加
      • 單株抗體生產的增加
    • 課題
      • 改善小鼠模型的必要性

第6章 各類型分析

  • 簡介
  • 近交類老鼠
  • 非近交類老鼠
  • 基因改造(基因剔除/基因敲入)老鼠
  • 混合/同類老鼠
  • 帶條件/外科的修復完畢老鼠
  • 自然發生突變老鼠

第7章 各技術分析

  • 簡介
  • 顯微注射
  • ES細胞注射
  • 細胞核的轉移酵素
  • 其他技術

第8章 各服務類別分析

  • 簡介
  • 繁殖服務
  • 冷凍保存服務
  • 檢疫服務
  • 再導出來服務
  • 模式、引入授權、服務
  • 遺傳基因檢驗服務
  • 其他服務

第9章 各疾病分析

  • 簡介
  • 腫瘤學小鼠模型
  • 免疫學及發炎研究小鼠模型
  • 糖尿病研究小鼠模型
  • 心臟血管研究小鼠模型
  • 中樞神經系統小鼠模型
  • 代謝及調整研究小鼠模型
  • 其他疾病研究小鼠模型

第10章 各類型分析

  • 簡介
  • 籠子
  • 飼料
  • 其他

第11章 各地區分析

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第12章 競爭環境

  • 概要
  • 市場佔有率分析
  • 競爭情形及趨勢
    • 合作、協定、策略性聯盟關係及合資企業
    • 輔助金及基金
    • 授權
    • 新產品發表
    • 產業擴張
    • 專利
    • 收購
    • 其他

第13章 企業簡介

  • 簡介
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
  • THE JACKSON LABORATORY
  • TACONIC BIOSCIENCES, INC.
  • ENVIGO
  • COVANCE, INC.
  • JANVIER LABS
  • HARBOUR ANTIBODIES BV
  • TRANSGENIC, INC.
  • GENOWAY SA
  • SAGE LABS, INC. (A SUBSIDIARY OF HORIZON DISCOVERY GROUP PLC)
  • INGENIOUS TARGETING LABORATORY

第14章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BT 2192

Mice models are indispensable tools in research activities with their capability to elucidate human disease processes, due to striking similarities between the anatomy, physiology, and genetics of humans and mice. These advantages promote scientific discovery, understanding of the functions of individual genes, mechanisms of different diseases, and the effectiveness and toxicities of various drug molecules. Mice models are the most popularly used animal models due to their small size, short generation time, accelerated lifespan, low cost, and requirement of less space. These factors help in accelerating the research and development of drug therapies.

Ongoing innovations in mice models, personalized medicine fuelling the demand for personalized humanized mice models, continuous support in the form of investments and grants, and increase in R&D activities of pharmaceutical industries are some of the factors that are expected to drive the growth of the global mice model market in the coming years.

Market players are continuously focusing on innovations in mice models for research on various human diseases. Growing innovations and advances in mice models are providing increased options to researchers to conduct research activities in particular diseases, which is a major factor driving market growth.

On the other hand, factors like advancements in genetic techniques for the development of genetically modified rats have led to the increased usage of rat models, thereby restraining the mice model market to some extent. In addition, advances in zebrafish model development, increased benefits from cryopreservation, regulations & laws for the ethical use of animals, and alternative methods to animal testing are some factors expected to restrain the growth of the market. Moreover, the continuous need for improved mice models is posing as a major challenge for the global mice model market.

In 2015, the inbred mice are estimated to account for the largest share of the global mice model market, by type while genetically engineered mice models are expected to be the fastest-growing market segment, owing to high investments in the development of new and innovative knockout models that also increases the application areas for the models.

In 2015, North America is expected to account for the largest share of the global mice model market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). North America's large share is attributed to the revised funding plans by NIH to enhance the reproducibility of results, rising demands for monoclonal antibody production, continued and responsible use of animals ensured by animal care organizations, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada.

The major players in the market are focusing on various strategies (agreements, partnerships, joint ventures, collaborations, geographic expansion, new product launches, funds/grants, licensing, patents, and acquisitions) to increase their market shares and establish a strong foothold in the global market.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the models and services offered by top players in the mice model market. The report analyzes the mice model market, by type, technology, disease, service, and mice care products.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the mice model market
  • Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for mice models & services across regions
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the mice model market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, and distribution networks of the leading players in the mice model market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
      • 2.2.1.1. Key data from secondary sources
    • 2.2.2. PRIMARY RESEARCH
      • 2.2.2.1. Key industry insights
      • 2.2.2.2. Key data from primary sources
      • 2.2.2.3. Key insights from primary sources
  • 2.3. MARKET SIZE ESTIMATION METHODOLOGY
  • 2.4. MARKET FORECAST METHODOLOGY
  • 2.5. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.6. ASSUMPTIONS

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. GLOBAL MICE MODEL MARKET
  • 4.2. GEOGRAPHIC ANALYSIS: MICE CARE PRODUCTS MARKET, BY TYPE
  • 4.3. MICE MODEL MARKET, BY TECHNOLOGY (2015 VS. 2020)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. Ongoing innovations in mice models
        • 5.3.1.1.1. Mice models for immune diseases
        • 5.3.1.1.2. Mice models for cancer
        • 5.3.1.1.3. Mice models for rare diseases
      • 5.3.1.2. Personalized medicine to fuel the demand for personalized humanized mice models
      • 5.3.1.3. Continuous support in the form of grants and investments
      • 5.3.1.4. Increase in R&D activities of pharmaceutical industries
      • 5.3.1.5. Increasing focus of associations on the development of embryonic stem (ES) cells as well as knockout and mutant mice
        • 5.3.1.5.1. International Mouse Phenotyping Consortium (IMPC)
        • 5.3.1.5.2. International Knockout Mouse Consortium (IKMC)
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. Increased usage of rat models
      • 5.3.2.2. Advances in zebrafish model development
      • 5.3.2.3. Increased benefits from cryopreservation
      • 5.3.2.4. Regulations and laws for ethical use of animals in research
        • 5.3.2.4.1. The Animal Welfare Act (AWA)
        • 5.3.2.4.2. Public Health Service Policy (PHS)on Humane Care and Use of Laboratory Animals
      • 5.3.2.5. Alternative methods to animal testing
    • 5.3.3. OPPORTUNITIES
      • 5.3.3.1. Rising demand of humanized mice models
      • 5.3.3.2. Increase in monoclonal antibody production
    • 5.3.4. CHALLENGE
      • 5.3.4.1. Need for improved mice models

6. MICE MODEL MARKET, BY TYPE

  • 6.1. INTRODUCTION
  • 6.2. INBRED MICE
  • 6.3. OUTBRED MICE
  • 6.4. GENETICALLY ENGINEERED (KNOCKOUT & KNOCKIN) MICE
  • 6.5. HYBRID/CONGENIC MICE
  • 6.6. CONDITIONED/SURGICALLY MODIFIED MICE
  • 6.7. SPONTANEOUS MUTANT MICE

7. MICE MODEL MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. MICROINJECTION
  • 7.3. EMBRYONIC STEM CELL INJECTION
  • 7.4. NUCLEAR TRANSFERASE
  • 7.5. OTHER TECHNOLOGIES
    • 7.5.1. GENETICALLY MODIFIED SPERM-MEDIATED GENE TRANSFER
    • 7.5.2. VIRUS/VECTOR-MEDIATED GENE TRANSFER
    • 7.5.3. LIPOSOME-MEDIATED DNA AND ELECTROPORATION OF DNA
    • 7.5.4. BIOLISTICS
    • 7.5.5. CRISPR/CAS9, TALENS, AND ZFNS

8. MICE MODEL MARKET, BY SERVICE

  • 8.1. INTRODUCTION
  • 8.2. BREEDING SERVICES
  • 8.3. CRYOPRESERVATION SERVICES
  • 8.4. QUARANTINE SERVICES
  • 8.5. REDERIVATION SERVICES
  • 8.6. MODEL IN-LICENSING SERVICES
  • 8.7. GENETIC TESTING SERVICES
  • 8.8. OTHER SERVICES

9. MICE MODEL MARKET, BY DISEASE

  • 9.1. INTRODUCTION
  • 9.2. ONCOLOGY MICE MODELS
    • 9.2.1. CONTINUOUS GRANTS/FUNDS TO SUPPORT CANCER RESEARCH STUDIES
    • 9.2.2. AGREEMENTS/COLLABORATIONS TO STRENGTHEN CANCER RESEARCH
    • 9.2.3. INTRODUCTION OF NEW MICE MODELS FOR SPECIFIC CANCERS
    • 9.2.4. EXPANSIONS TO SUPPORT CANCER RESEARCH FACILITIES
  • 9.3. MICE MODELS FOR IMMUNOLOGY AND INFLAMMATION STUDIES
  • 9.4. MICE MODELS FOR DIABETES STUDIES
  • 9.5. MICE MODELS FOR CARDIOVASCULAR STUDIES
  • 9.6. MICE MODELS FOR CENTRAL NERVOUS SYSTEM (CNS) STUDIES
  • 9.7. MICE MODELS FOR METABOLISM AND REGULATION STUDIES
  • 9.8. MICE MODELS FOR OTHER DISEASE STUDIES

10. MICE CARE PRODUCTS MARKET, BY TYPE

  • 10.1. INTRODUCTION
  • 10.2. CAGES
  • 10.3. FEED
  • 10.4. BEDDING
  • 10.5. OTHERS

11. MICE MODEL MARKET, BY REGION

  • 11.1. INTRODUCTION
  • 11.2. NORTH AMERICA
    • 11.2.1. U.S.
      • 11.2.1.1. Revised funding plans by the NIH to enhance reproducibility of results
      • 11.2.1.2. Growing biomedical research in the U.S.
      • 11.2.1.3. Monoclonal antibody production to augment the use of mice models
      • 11.2.1.4. Continued and responsible use of animals ensured by Animal Care Organizations
      • 11.2.1.5. Development of biosimilars boosting the demand for preclinical services
      • 11.2.1.6. Preclinical activities by CROs and pharmaceutical R&D
      • 11.2.1.7. Partnerships between CROs and pharmaceutical companies
    • 11.2.2. CANADA
      • 11.2.2.1. Growing stem cell research activities in Canada
  • 11.3. EUROPE
    • 11.3.1. GERMANY
      • 11.3.1.1. Launch of Pro-Test Deutschland
      • 11.3.1.2. Flourishing biotechnology industry
    • 11.3.2. U.K.
      • 11.3.2.1. Investors demand strong statistics for animal studies in the U.K.
      • 11.3.2.2. Increase in cell therapy preclinical research
    • 11.3.3. FRANCE
      • 11.3.3.1. Funding for rare disease projects in France
    • 11.3.4. REST OF EUROPE (ROE)
      • 11.3.4.1. Improving biomedical industry in Russia
      • 11.3.4.2. Growth in biosimilars market calls for increased preclinical activities
      • 11.3.4.3. Focus on rare disease research projects
      • 11.3.4.4. Events conducted by animal care associations to promote the ethical use of mice
      • 11.3.4.5. Increase in tailored mice models for diseases like cancer
  • 11.4. ASIA-PACIFIC
    • 11.4.1. CHINA
      • 11.4.1.1. International alliances for R&D activities in China
      • 11.4.1.2. Growing foray of pharmaceutical and mice model suppliers in China
      • 11.4.1.3. Increasing investments from government and private sectors in China's life sciences sector
      • 11.4.1.4. Initiatives to reduce longer approval times
      • 11.4.1.5. Mandatory animal testing for all pharmaceutical drugs and cosmetics in China
      • 11.4.1.6. Intellectual property (IP) breaches, a challenge for the Chinese market
    • 11.4.2. JAPAN
      • 11.4.2.1. Growth in biomedical and medical research in Japan
      • 11.4.2.2. Research into regenerative medicines
    • 11.4.3. INDIA
      • 11.4.3.1. Growing presence of global players
      • 11.4.3.2. Development of bioclusters to boost India's biotechnology industry
      • 11.4.3.3. R&D activities by Indian pharmaceutical companies to boost preclinical research
      • 11.4.3.4. Likely shift of outsourcing preclinical activities from India towards European nations
      • 11.4.3.5. Limited infrastructural facilities in India, a major hindrance to the mice model market
      • 11.4.3.6. Weak intellectual property environment in India
    • 11.4.4. REST OF ASIA-PACIFIC (ROAPAC)
      • 11.4.4.1. Influx of international players
      • 11.4.4.2. Ongoing biomedical research activities in Australia to strengthen the market
      • 11.4.4.3. Growth in translational and biomedical research in Singapore
      • 11.4.4.4. Increase in animal research in Malaysia
      • 11.4.4.5. Rising pharmaceutical and biotechnology R&D activities in Korea
  • 11.5. REST OF WORLD (ROW)
      • 11.5.1.1. Pharmaceutical, biotechnology, and research industries in Brazil to bolster the market
      • 11.5.1.2. Favorable business environment for pharmaceutical and biotechnology industries in Saudi Arabia and the UAE

12. COMPETITIVE LANDSCAPE

  • 12.1. OVERVIEW
  • 12.2. MICE MODEL MARKET: MARKET SHARE ANALYSIS (2014)
    • 12.2.1. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • 12.2.2. THE JACKSON LABORATORY
    • 12.2.3. TACONIC BIOSCIENCES, INC.
    • 12.2.4. HARLAN LABORATORIES, INC. (ENVIGO)
  • 12.3. COMPETITIVE SITUATION AND TRENDS
    • 12.3.1. COLLABORATIONS, AGREEMENTS, STRATEGIC ALLIANCES PARTNERSHIPS, AND JOINT VENTURES
    • 12.3.2. GRANTS & FUNDS
    • 12.3.3. LICENSING
    • 12.3.4. NEW PRODUCT LAUNCHES
    • 12.3.5. EXPANSIONS
    • 12.3.6. PATENTS
    • 12.3.7. ACQUISITIONS
    • 12.3.8. OTHERS

13. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 13.1. INTRODUCTION
  • 13.2. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
  • 13.3. THE JACKSON LABORATORY
  • 13.4. TACONIC BIOSCIENCES, INC.
  • 13.5. ENVIGO
  • 13.6. COVANCE, INC.
  • 13.7. JANVIER LABS
  • 13.8. HARBOUR ANTIBODIES BV
  • 13.9. TRANSGENIC, INC.
  • 13.10. GENOWAY SA
  • 13.11. SAGE LABS, INC. (A SUBSIDIARY OF HORIZON DISCOVERY GROUP PLC)
  • 13.12. INGENIOUS TARGETING LABORATORY

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

14. APPENDIX

  • 14.1. DISCUSSION GUIDE
  • 14.2. COMPANY DEVELOPMENTS (2012-2015)
    • 14.2.1. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • 14.2.2. THE JACKSON LABORATORY (JAX)
    • 14.2.3. TACONIC BIOSCIENCES INC.
    • 14.2.4. ENVIGO
    • 14.2.5. COVANCE, INC.
    • 14.2.6. TRANSGENIC, INC.
    • 14.2.7. GENOWAY SA
    • 14.2.8. SAGE LABS, INC.
  • 14.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 14.4. AVAILABLE CUSTOMIZATIONS
  • 14.5. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: ONGOING INNOVATIONS IN MICE MODELS ARE PROPELLING THE GROWTH OF GLOBAL MICE MODEL MARKET
  • TABLE 2: INCREASED USAGE OF RAT MODELS IS LIMITING THE ADOPTION OF MICE MODELS IN RESEARCH
  • TABLE 3: INCREASE IN MONOCLONAL ANTIBODY PRODUCTION USING MICE MODELS HAS A HUGE POTENTIAL FOR THE MICE MODEL MARKET
  • TABLE 4: NEED FOR IMPROVED MICE MODELS IS A MAJOR MARKET CHALLENGE
  • TABLE 5: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 6: INBRED MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 7: OUTBRED MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 8: GENETICALLY ENGINEERED MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 9: HYBRID/CONGENIC MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 10: CONDITIONED/SURGICALLY MODIFIED MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 11: SPONTANEOUS MUTANT MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 12: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 13: MICROINJECTION MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 14: EMBRYONIC STEM CELL INJECTION MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 15: NUCLEAR TRANSFERASE MARKET SIZE, BY COUNTRY, 2013-2020 (USD THOUSAND)
  • TABLE 16: OTHER MICE MODEL TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2013-2020 (USD THOUSAND)
  • TABLE 17: GLOBAL MICE MODEL MARKET, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 18: MICE MODEL MARKET SIZE FOR BREEDING SERVICES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 19: MICE MODEL MARKET SIZE FOR CRYOPRESERVATION SERVICES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 20: MICE MODEL MARKET SIZE FOR QUARANTINE SERVICES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 21: MICE MODEL MARKET SIZE FOR REDERIVATION SERVICES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 22: MICE MODEL MARKET SIZE FOR MODEL IN-LICENSING SERVICES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 23: MICE MODEL MARKET SIZE FOR GENETIC TESTING SERVICES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 24: MICE MODEL MARKET SIZE FOR OTHER SERVICES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 25: GLOBAL MICE MODEL MARKET, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 26: RECENT CANCER RESEARCH STUDIES USING MICE MODELS
  • TABLE 27: ONCOLOGY MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 28: MICE MODEL MARKET FOR IMMUNOLOGY AND INFLAMMATION STUDIES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 29: MICE MODELS MARKET FOR DIABETES STUDIES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 30: MICE MODELS MARKET FOR CARDIOVASCULAR STUDIES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 31: RECENT CNS DISORDER-RELATED RESEARCH STUDIES USING MICE MODELS
  • TABLE 32: MICE MODEL MARKET FOR CENTRAL NERVOUS SYSTEM STUDIES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 33: MICE MODEL MARKET FOR METABOLISM AND REGULATION STUDIES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 34: MICE MODEL MARKET FOR OTHER DISEASE STUDIES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 35: GLOBAL MICE CARE PRODUCTS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 36: MICE CARE PRODUCTS MARKET SIZE FOR CAGES, BY REGION, 2013-2020 (USD THOUSAND)
  • TABLE 37: MICE CARE PRODUCTS MARKET SIZE FOR FEED, BY REGION, 2013-2020 (USD THOUSAND)
  • TABLE 38: MICE CARE PRODUCTS MARKET SIZE FOR BEDDING, BY REGION, 2013-2020 (USD THOUSAND)
  • TABLE 39: OTHER MICE CARE PRODUCTS MARKET SIZE, BY REGION, 2013-2020 (USD THOUSAND)
  • TABLE 40: MICE MODEL MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 41: NORTH AMERICA: MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 42: NORTH AMERICA: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 43: NORTH AMERICA: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 44: NORTH AMERICA: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 45: NORTH AMERICA: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 46: NORTH AMERICA: MICE CARE PRODUCTS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 47: NIH FUNDING FOR PROJECTS RELATED TO ANIMAL MODELS
  • TABLE 48: ASSOCIATIONS DIRECTLY RELATED TO THE ANIMAL MODEL MARKET
  • TABLE 49: ASSOCIATIONS INDIRECTLY RELATED TO THE ANIMAL MODEL MARKET
  • TABLE 50: U.S.: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 51: U.S.: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 52: U.S.: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 53: U.S.: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 54: CANADA: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 55: CANADA: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 56: CANADA: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 57: CANADA: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 58: EUROPE: MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 59: EUROPE: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 60: EUROPE: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 61: EUROPE: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 62: EUROPE: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 63: EUROPE: MICE CARE PRODUCTS, BY TYPE, 2013-2020 (USD THOUSAND)
  • TABLE 64: GERMANY: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 65: GERMANY: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 66: GERMANY: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 67: GERMANY: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 68: U.K.: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 69: U.K.: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 70: U.K.: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 71: U.K.: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 72: FRANCE: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 73: FRANCE: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD THOUSAND)
  • TABLE 74: FRANCE: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 75: FRANCE: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 76: STAGES OF PHARMA 2020 STRATEGY
  • TABLE 77: EUROPEAN ANIMAL CARE ASSOCIATIONS AND THEIR EVENTS
  • TABLE 78: ROE: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 79: ROE: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 80: ROE: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 81: ROE: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 82: ASIA-PACIFIC: MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 83: ASIA-PACIFIC: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 84: ASIA-PACIFIC: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD THOUSAND)
  • TABLE 85: ASIA-PACIFIC: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 86: ASIA-PACIFIC: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 87: ASIA-PACIFIC: MICE CARE PRODUCTS, BY TYPE, 2013-2020 (USD THOUSAND)
  • TABLE 88: CHINA: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 89: CHINA: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD THOUSAND)
  • TABLE 90: CHINA: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD THOUSAND)
  • TABLE 91: CHINA: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 92: JAPAN: SIGNIFICANT PARTNERSHIPS
  • TABLE 93: JAPAN: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 94: JAPAN: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD THOUSAND)
  • TABLE 95: JAPAN: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD THOUSAND)
  • TABLE 96: JAPAN: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 97: STUDY RESULTS REGARDING R&D EXPENDITURE OF 25 PHARMACEUTICAL COMPANIES
  • TABLE 98: INDIA: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 99: INDIA: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD THOUSAND)
  • TABLE 100: INDIA: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD THOUSAND)
  • TABLE 101: INDIA: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 102: ROAPAC: PLAYER ACTIVITY, 2013 TO 2015
  • TABLE 103: REST OF APAC: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 104: REST OF APAC: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD THOUSAND)
  • TABLE 105: REST OF APAC: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD THOUSAND)
  • TABLE 106: REST OF APAC: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 107: ROW: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD THOUSAND)
  • TABLE 108: ROW: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD THOUSAND)
  • TABLE 109: ROW: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD THOUSAND)
  • TABLE 110: ROW: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD THOUSAND)
  • TABLE 111: ROW: MICE CARE PRODUCTS, BY TYPE, 2013-2020 (USD THOUSAND)
  • TABLE 112: COLLABORATIONS, AGREEMENTS, STRATEGIC ALLIANCES, JOINT VENTURES, AND PARTNERSHIPS (2012-2015)
  • TABLE 113: GRANTS & FUNDS, 2012-2015
  • TABLE 114: LICENSING (2012-2015)
  • TABLE 115: NEW PRODUCT LAUNCHES (2012-2015)
  • TABLE 116: KEY PLAYERS FOCUSING ON EXPANSIONS (2012-2015)
  • TABLE 117: PATENTS (2012-2015)
  • TABLE 118: ACQUISITIONS (2012-2015)
  • TABLE 119: KEY PLAYERS FOCUSING ON OTHER STRATEGIES (2012-2015)

LIST OF FIGURES

  • FIGURE 1: GLOBAL MICE MODEL MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: SAMPLING FRAME: PRIMARY RESEARCH
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 5: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 6: RESEARCH DESIGN
  • FIGURE 7: DATA TRIANGULATION METHODOLOGY
  • FIGURE 8: NORTH AMERICA DOMINATES THE GLOBAL MICE MODEL MARKET
  • FIGURE 9: CRYOPRESERVATION SERVICES MARKET TO GROW AT THE HIGHEST CAGR FROM 2015 TO 2020
  • FIGURE 10: ASIA-PACIFIC IS EXPECTED TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
  • FIGURE 11: ONGOING INNOVATIONS IN MICE MODELS TO SPUR MARKET GROWTH DURING THE FORECAST PERIOD
  • FIGURE 12: NORTH AMERICA DOMINATED THE MICE CARE PRODUCTS MARKET IN 2015
  • FIGURE 13: ASIA-PACIFIC MARKET TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 14: MICROINJECTION TECHNOLOGY COMMANDED THE LARGEST SHARE IN 2015
  • FIGURE 15: GLOBAL MICE MODEL MARKET SEGMENTATION
  • FIGURE 16: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17: GENETICALLY ENGINEERED MICE TO BE THE FASTEST GROWING SEGMENT
  • FIGURE 18: MICROINJECTION TECHNOLOGY COMMANDED THE LARGEST SHARE OF MICE MODEL MARKET IN 2015
  • FIGURE 19: MICE MODEL MARKET, BY SERVICE
  • FIGURE 20: BREEDING SERVICES ACCOUNTED FOR THE LARGEST SHARE OF THE MICE MODEL MARKET IN 2015
  • FIGURE 21: MICE MODEL MARKET, BY DISEASE
  • FIGURE 22: ONCOLOGY MICE MODELS TO DOMINATE THE MICE MODEL MARKET IN 2015
  • FIGURE 23: MICE CARE PRODUCTS MARKET, BY TYPE
  • FIGURE 24: CAGES ACCOUNTED FOR THE LARGEST SHARE OF THE MICE CARE PRODUCTS MARKET IN 2015
  • FIGURE 25: ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR IN THE MICE MODEL MARKET DURING THE FORECAST PERIOD
  • FIGURE 26: THE U.S. COMMANDED THE LARGEST SHARE IN THE MICE MODEL MARKET IN NORTH AMERICA IN 2015
  • FIGURE 27: GERMANY DOMINATED THE EUROPEAN MICE MODEL MARKET IN 2015
  • FIGURE 28: NUMBER OF CELL THERAPY PRECLINICAL STUDIES LISTED IN THE PRECLINICAL RESEARCH DATABASE IN THE U.K., 2013-2015
  • FIGURE 29: CHINA: THE FASTEST GROWING COUNTRY IN THE ASIA-PACIFIC MICE MODEL MARKET
  • FIGURE 30: CHINA PHARMA PARTNERING ACTIVITY BY STAGE - 2009-2014
  • FIGURE 31: ONCOLOGY MICE MODELS TO DOMINATE THE ROW MICE MODELS MARKET, BY DISEASES
  • FIGURE 32: MAJOR PLAYERS FOCUSED ON INORGANIC GROWTH STRATEGIES
  • FIGURE 33: MICE MODEL MARKET SHARE, BY KEY PLAYER, 2014
  • FIGURE 34: BATTLE FOR MARKET SHARE: MAJOR COLLABORATIONS, AGREEMENTS, STRATEGIC ALLIANCES, JOINT VENTURES, AND PARTNERSHIPS FORMED THE KEY STRATEGY (2012-2015)
  • FIGURE 35: KEY PLAYERS FOCUSING ON COLLABORATIONS, AGREEMENTS, STRATEGIC ALLIANCES, JOINT VENTURES, AND PARTNERSHIPS (2012-2015)
  • FIGURE 36: KEY PLAYERS FOCUSING ON GRANTS & FUNDS (2012-2015)
  • FIGURE 37: KEY PLAYERS FOCUSING ON LICENSING (2012-2015)
  • FIGURE 38: KEY PLAYERS FOCUSING ON NEW PRODUCT LAUNCHES (2012-2015)
  • FIGURE 39: KEY PLAYERS FOCUSING ON EXPANSIONS (2012-2015)
  • FIGURE 40: KEY PLAYERS FOCUSING ON PATENTS (2012-2015)
  • FIGURE 41: KEY PLAYERS FOCUSING ON ACQUISITIONS (2012-2015)
  • FIGURE 42: KEY PLAYERS FOCUSING ON OTHER STRATEGIES (2012-2015)
  • FIGURE 43: BUSINESS FOCUS OF TOP MARKET PLAYERS
  • FIGURE 44: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT
  • FIGURE 45: THE JACKSON LABORATORY: COMPANY SNAPSHOT
  • FIGURE 46: COVANCE, INC.: COMPANY SNAPSHOT
  • FIGURE 47: GENOWAY SA: COMPANY SNAPSHOT
Back to Top